Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Change in Account Payables (2017 - 2025)

Sutro Biopharma's Change in Account Payables history spans 9 years, with the latest figure at $2.7 million for Q3 2025.

  • For Q3 2025, Change in Account Payables rose 2281.3% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $1.1 million, up 67.91%, while the annual FY2024 figure was $706000.0, 85.33% down from the prior year.
  • Change in Account Payables for Q3 2025 was $2.7 million at Sutro Biopharma, up from -$3.8 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.1 million in Q4 2024 and bottomed at -$3.8 million in Q2 2025.
  • The 5-year median for Change in Account Payables is -$462000.0 (2021), against an average of $208315.8.
  • The largest annual shift saw Change in Account Payables plummeted 1058.08% in 2024 before it skyrocketed 2281.3% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at -$1.8 million in 2021, then skyrocketed by 47.24% to -$937000.0 in 2022, then skyrocketed by 532.98% to $4.1 million in 2023, then grew by 1.58% to $4.1 million in 2024, then tumbled by 34.89% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Change in Account Payables are $2.7 million (Q3 2025), -$3.8 million (Q2 2025), and -$1.9 million (Q1 2025).